Hans Brightbill

Scientific Director, In Vivo Pharmacology - Inflammation Research, Amgen

San Francisco, California, United States

About

Experience

  • Scientific Director, In Vivo Pharmacology - Inflammation at Amgen
    Jun 2024 - Present · 2 yrs 2 mos

  • Review Editor at Frontiers in Immunology
    Nov 2022 - Present · 3 yrs 9 mos

  • Genentech (18 yrs 6 mos)
    • Voting member, Institutional Animal Care and Use Committee (IACUC)
      Jan 2023 - Jun 2024 · 1 yr 6 mos

    • Principal Scientific Manager (Group Leader), Translational Immunology
      Jul 2020 - Jun 2024 · 4 yrs

      Publications: Sun. T., Huang, Z., Liang, W.C., Yin, J., Lin, W.Y., Wu, J., Vernes, J.M., Lutman, J., Caplazi, P., Jeet, S., Wong, T., Wong, M., DePianto, D.J., Morshead, K.B., Sun, K.H., Modrusan, Z., Vander Heiden, J.A., Abbas, A.R., Zhang, H., Xu, M., N'Diaye, E.N., Roose-Girma, M., Wolters, P.J., Yadav, R., Sukumaran, S., Ghilardi, N., Corpuz, R., Emson, C., Meng, Y.G., Ramalingam, T.R., Lupardus, P., Brightbill, H.D., Seshasayee, D., Wu, Y., Arron, J.R. (2021) TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis. Sci. Transl. Med. 13(605):eabe0407. doi: 10.1126/scitranslmed.abe0407. Gu, M., Zhou, X. , Sohn, J.H., Zhu, L-L. , Jie, Z., Yang, J-Y. , Zheng, X., Xie, X., Yang, J., Shi, Y., Brightbill, H., Kim, J.B., Wang, J., Cheng, X., S-C. Sun. (2021) NF-kB inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nat Immunol. 22:530. doi: 10.1038/s41590-021-00892-7. Presentations: Anti-Fibrotic Drug Development Conference (AFDD) 2020. “A Comparison of CDA-HFD & High Cholesterol Diet Induced NASH Models Using Automated Quantitative Image Analysis and Deuterated Hydroxyproline Mass Spectrometry”. November 2020. Virtual Conference. IPF Summit 2020. Panel discussion: Preclinical Fibrosis Models. August 2020.

    • Interim Fibrosis Disease Area Strategy Lead
      Jul 2021 - Jan 2023 · 1 yr 7 mos

  • UC Berkeley (5 yrs 9 mos)
    • Associate Specialist
      Jul 2005 - Jan 2006 · 7 mos

      Research on the role of c-Abl in early B cell development and survival. 2004-2005: National Institutes of Health Fellowship, #CA09179-29.

    • Post-doctoral Fellow
      May 2000 - Jun 2005 · 5 yrs 2 mos

      AWARDS: 2001-2004. Leukemia and Lymphoma Society Fellowship #5325-02.

  • UCLA, Department of Microbiology and Immunology, School of Medicine (6 yrs 1 mo)
    • Graduate Student
      1994 - 2000 · 6 yrs

      Research on cytokine gene regulation and the innate immune response to microbial lipid antigens through Toll-like Receptors.

    • Teaching Assistant
      1995 - 1996 · 1 yr

      Teaching assistant for undergraduate courses in Immunology and Molecular Biology.